Prescriber

Sitagliptin: first DPP‐4 inhibitor to treat type 2 diabetes

Authors

Steve Chaplin, Andrew Krentz

Abstract

Sitagliptin (Januvia) is the first of a new class of drugs in the treatment of type 2 diabetes. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Krentz comments on its potential place in the treatment of type 2 diabetes. Copyright © 2008 Wiley Interface Ltd

Digital Object Identifier (DOI)

10.1002/psb.174 About DOI

Bookmark and Share

Search the Site

Search

Therapeutics Plus

Learning Central

 ad block right